Hemostatic Risk Factors and Arterial Thrombotic Disease

Alexander P. Reiner; David S. Siscovick; Frits R. Rosendaal

doi:10.1055/s-0037-1615638

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(04): 584-595
DOI: 10.1055/s-0037-1615638

Review Articles

Schattauer GmbH

Hemostatic Risk Factors and Arterial Thrombotic Disease

Alexander P. Reiner

¹Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

,

David S. Siscovick

¹Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

,

Frits R. Rosendaal

²The Hemostasis and Thrombosis Research Center and Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands

› Author Affiliations

Abstract

Summary

The pathogenesis of arterial thrombotic disease involves multiple genetic and environmental factors related to atherosclerosis and thrombosis. Acute thrombosis at the site of a ruptured, lipid-rich atherosclerotic plaque is the usual precipitating event in the transition from stable or subclinical atherosclerotic disease to acute myocardial infarction (MI), stroke, or peripheral arterial occlusion (1). Pathologic studies of coronary arteries in acute MI suggest that the acute thrombosis likely involves activation of both platelets and the coagulation system.

Full Text

References

References
1 Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-20.
2 Rentrop KP. Thrombi in acute coronary syndromes. Revisted and revised. Circulation 2000; 101: 1619-26.
3 Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work. JAMA 1995; 274: 801-6.
4 Hebert PR, Ridker PM, Fuster V, Hennekens CH. Antithrombotic agents in the secondary and primary prevention of cardiovascular diseases in high and usual risk individuals. In: Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology. Verstraete M, Fuster V, Topol EJ. eds. Philadelphia: Lippincott-Raven Publishers; 1998: 461-70.
5 Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med 2000; 45: 391-417.
6 Kullo IJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. Mayo Clin Proc 2000; 75: 369-80.
7 Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
8 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analysis of prospective studies. JAMA 1998; 279: 1477-82.
9 Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
10 Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
11 Folsom AR. Fibrinogen and cardiovascular risk markers. Blood Coagul Fibrinol 1999; 10: S13-S15.
12 Behar S. Lowering fibrinogen levels: clinical update. Blood Coagul Fibrinol 1999; 10: S41-S43.
13 Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of hepG2 cells with Bβ cDNA specifically enhances synthesis of the three component chains of fibrinogen. J Biol Chem 1990; 265: 6389-93.
14 Humphries SE, Henry JA, Montgomery HE. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinol 1999; 10: S17-S21.
15 Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou J-P, Scarabin P-Y, Bara L, Green F, Cambien F. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM study. Circulation 1996; 93: 440-9.
16 Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen Bβ 448 polymorphism, fibrinogen levels, and acute coronary disease. Arterioscler Thromb Vasc Biol 1997; 17: 589-94.
17 Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, Ikeda U, Shimada K, Matsuo M. Genetic variation in the promoter region of the β-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coagul Fibrinol 1998; 9: 373-9.
18 Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455→A) in the β-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9,127 individuals based on The Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-9.
19 Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H, Hehrlein FW, Waas W, Eberbach A. Positive association of the β fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost 1997; 77: 1120-6.
20 Meade TW, Ruddock V, Stirling Y, Chakrabati R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-9.
21 Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-44.
22 Smith FB, Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
23 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 1102-8.
24 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms – the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
25 Mennen LI, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review. Thromb Haemost 1996; 76: 492-9.
26 Hunault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
27 Iacoviello L, Di Castelnuovo A, de Knijff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
28 Moor E, Silveira A, van’t Hooft F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
29 Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambie F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
30 Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998; 80: 281-5.
31 Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVIIC levels in relation to acute cerebrovascular disease and post stroke mortality. Stroke 1997; 28: 816-21.
32 Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII ABO blood group, and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
33 Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999; 105: 110-6.
34 Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19: 1776-83.
35 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
36 Blann AD, McCollum CN. Von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinol 1999; 10: 375-80.
37 Rosendaal FR, Varekamp I, Brocker-Vriends AH, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briët E. Mortality and causes of death in Dutch haemophiliacs, 1973-1986. Br J Haematol 1989; 71: 71-6.
38 Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 823-7.
39 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-venous thrombosis. Lancet 1995; 345: 152-5.
40 Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfus F, Oron D, Neufeld H, Riss E. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N Engl J Med 1971; 285: 1348-53.
41 Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eiken-boom JCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998; 79: 323-7.
42 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 8: 2766-70.
43 Kohler HP, Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVAL34Leu) affects cross-linking activity. Thromb Haemost 1998; 80: 704.
44 Kohler HP, Stickland MH, Ossei-Gerning N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13.
45 Wartiovaara U, Perola M, Mikkola H, Tötterman K, Savolainen V, Penttilä A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis 1999; 142: 295-300.
46 Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarenco P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. Blood 2000; 95: 586-91.
47 Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906.
48 Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val34Leu: a novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-816.
49 Ariëns RAS, Phillippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-95.
50 Redondo M, Watzke HH, Stucki B, Sulzer I, Demarmels Biasiutti F, Binder BR, Furlan M, Lämmle B. Wuillermin.. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
51 De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-8.
52 Zöller B, de Frutos PG, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. Thromb Haemost 1998; 79: 802-7.
53 Barinagarrementeria F, Cantú-Brito C, De La Peña A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study. Stroke 1994; 25: 287-90.
54 Douay X, Lucas C, Caron C, Goudemand J, Leys D. Antithrombin, protein C, and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998; 98: 124-7.
55 Munts AG, van Genderen PJJ, Dippel DWJ, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischemia. J Neurol 1998; 245: 21-5.
56 Margaglione M, D’Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G. Inherited prothrombotic conditions and premature ischemic stroke. Sex differences in the association with factor V Leiden. Arterioscler Thromb Vasc Biol 1999; 19: 1751-6.
57 Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch Neurol 1999; 56: 967-71.
58 Nowak-Göttl U, Sträter R, Heinecke A, Junker R, Koch HG, Schuierer G. von Eckardstein.. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999; 94: 3678-82.
59 Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
60 Ganesan V, McShane MA, Liesner R, Cookson J, Hann I, Kirkham FJ. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998; 65: 508-11.
61 McColl MD, Chalmers EA, Thomas A, Sproul A, Healey C, Rafferty I, McWilliam R, Euson P. Factor V Leiden, prothrombin 20210 G→A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999; 81: 690-4.
62 Koster T, Rosendaal F, de Ronde H, Briët E, Vandenbrouke J, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
63 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
64 Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
65 Emmerich J, Poirier O, Evans A, Marques-vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
66 Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506Gln factor V mutation in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
67 Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 GA mutation for coronary artery disease and myocardial infarction. J Molec Med 1995; 73: 521-4.
68 Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998; 79: 912-5.
69 Dunn ST, Roberts CR, Schecter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 1998; 91: 91-9.
70 Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999; 81: 208-13.
71 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
72 Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1995; 1: 185.
73 Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94: 46-51.
74 Vargas M, Soto I, Pinto CR, Urgelles MF, Batalla A, Rodriquez-Reguero J, Cortina A, Alvarez V, Coto E. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul Fibrinol 1999; 10: 39-41.
75 Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth Jr WT, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
76 Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
77 Catto A, Carter A, Ireland H, Bayston TA, Phillippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to development of stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-5.
78 De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
79 Voetsch B, Damasceno BP, Camargo ECS, Massaro A, Bacheschi LA, Scaff M, Annichino-Bizzachi JM, Arruda VR. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000; 83: 229-33.
80 Longstreth Jr WT, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-80.
81 Zenz W, Bodó Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Poier R, Höfler G, Mannhalter C, Muntean W. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke. Thromb Haemost 1998; 80: 763-6.
82 Foley PWX, Irvine CD, Standen GR, Morse C, Smith FT, McGrath C, Baird RN, Lamont PM. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg 1997; 5: 157-60.
83 Sampram ESK, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998; 28: 624-9.
84 Renner W, Köppel H, Brodmann M, Pabst E, Schallmoser K, Toplak H, Wascher TC, Pilger E. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease. Thromb Haemost 2000; 83: 20-2.
85 Van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-9.
86 Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999; 99: 614-9.
87 Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Stone WH, Blangero J, Fontcuberta J. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-51.
88 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
89 Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
90 Corral J, Gonzalez-Conejero R, Lozano ML, River J, Heras I, Vicente V. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997; 99: 304-7.
91 Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998; 80: 878-80.
92 Prohaska W, Schmidt M, Mannebach H, Gleichmann U, Kleesiek K. The prevalence of the prothrombin 20210 G→A mutation is not increased in angiographically confirmed coronary artery disease. Thromb Haemost 1999; 81: 161-2.
93 Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999; 81: 861-4.
94 Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
95 Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJP, Reitsma PH. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
96 Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997; 90: 1747-50.
97 Bentolila S, Ripoli L, Drouet L, Mazoyer E. Thrombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young. Stroke 1997; 28: 1846.
98 Honda S, Honda Y, Bauer B, Ruan C, Kunicki TJ. The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin β₃ . Blood 1995; 86: 234-42.
99 Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
100 Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96: 1424-31.
101 Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, März W, Scharf RE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen Ib (HPA-1b/Pl^A2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. Thromb Haemost 1998; 79: 731-5.
102 Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvänen AC. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Molec Genet 1998; 7: 1453-62.
103 Herrmann S-M, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The Leu ³³/Pro polymorphism (Pl^A1/Pl^A2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Thromb Haemost 1997; 77: 1179-81.
104 Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM, Felix SB, Roots I, Baumann G, Stangl K. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter intervention: a case-controlled study. Lancet 1999; 353: 708-12.
105 Böttiger C, Kastrati A, Koch W, Mehilli J, Seidl H, Schömig K, von Beckerath N, Schömig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. Thromb Haemost 2000; 83: 559-62.
106 Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. Pl^A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
107 Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless W, Wu KK. Prospective study of platelet Pl^A1/A2 polymorphism, platelet activation, and incidence of coronary heart disease. Blood 1998; 92 (Suppl. 01) 304a-305a.
108 Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, Whitsett C, Rawlins P, Evatt BL. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. Chest 1999; 116: 880-6.
109 Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP, III a Pl^A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler Thromb Vasc Biol 1998; 18: 1124-31.
110 Wagner KR, Giles WH, Johnson CJ, Ou C-Y, Bray PF, GoldschmidtClermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD, Wityk RJ, Wozniak MA, Price TR, Kittner SJ. Platelet glycoprotein receptor IIIa polymorphism Pl^A2 and ischemic stroke risk. Stroke 1998; 29: 581-5.
111 Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis – role of HPA-1b polymorphism in platelet function. Blood Coag Fibrinol 1997; 8: 284-90.
112 Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Wille-brand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28: 1392-5.
113 Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D’Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa PL^A2 polymorphism. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 1142-7.
114 Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendirx C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GPIIIa PL^A polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-8.
115 Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger J, Aiach M, Rendu F. Interdonor variability of platelet response to thrombin receptor activation: influence of PL^A2 polymorphism. Br J Haematol 1997; 99: 801-7.
116 Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (Pl^A2): no association with platelet fibrinogen binding. Br J Haematol 1999; 105: 664-6.
117 Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl^A2 polymorphism of integrin β₃ enhances outside-in signaling and adhesive functions. J Clin Invest 2000; 105: 793-802.
118 Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu Kaisa Penttilä A, Karhunen PJ. Glycoprotein IIIa Pl ^A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999; 19: 2573-8.
119 Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin α₂β₁ density is associated with two silent polymorphisms in the α₂ gene coding sequence. Blood. 1997; 89: 1939-43.
120 Kritzik M, Savage B, Nugent DJ, Sentoso S, Ruggieri ZM, Kunicki TJ. Nucleotide polymorphisms in the α₂ gene define multiple alleles that are associated with differences in platelet α₂β₁ density. Blood 1998; 92: 2382-8.
121 Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the α₂ gene in platelet GP Ia collagen receptor expression and function. Effect in thromboembolic diseases. Thromb Haemost 1999; 81: 951-6.
122 Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C₈₀₇T gene polymorphism with non-fatal myocardial infarction in younger patients. Blood 1999; 93: 2449-53.
123 Moshfegh K, Wuillemin WA, Redondo M, Lämmle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study. Lancet 1999; 353: 351-4.
124 Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The α₂ gene coding sequence T807/A873 of the platelet collagen receptor integrin α₂β₁ might be a genetic risk factor for the development of stroke in younger patients. Blood 1999; 93: 3583-6.
125 Reiner AP, Kumar PN, Schwartz SM, Longstreth Jr WT, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000; 31: 1628-33.
126 Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, Daly ME. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. Br J Haematol 1999; 106: 771-6.
127 Lopez JA, Ludwig EH, McCarthy BJ. Polymorphism of human platelet glycoprotein Iba results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region: structure/function implications. J Biol Chem 1992; 267: 10055-61.
128 Mazzucato M, Pradelles P, de Angelis V, Steffan A, de Marco L. Frequency and functional relevance of genetic threonine¹⁴⁵/methionine¹⁴⁵ dimorphism in platelet glycoprotein Ib in Italian population. Tranfusion 1996; 36: 891-4.
129 Li CQ, Garner SF, Davies J, Smethurst PA, Wardell MR, Ouwehand WH. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIbα express HPA-2 epitopes and show equal binding of von Willebrand factor. Blood 2000; 95: 205-1.
130 Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 3281-6.
131 Gonzales-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998; 92: 2771-6.
132 Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K. Association between platelet glycoprotein Ibα genotype and ischemic cerebrovascular disease. Stroke 2000; 31: 493-7.
133 Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, McGregor I, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-6.
134 Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
135 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
136 Thörgersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 1998; 98: 2241-7.
137 Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-33.
138 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci 1992; 89: 6998-7002.
139 Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC study – Atherosclerosis Risk in Communities Study. Circulation 1995; 91: 284-90.
140 Cessari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 1999; 19: 1378-86.
141 Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA/ plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997; 96: 761-8.
142 Chandler WL, Stratton JR. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. Am J Clin Pathol 1994; 102: 248-52.
143 Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in hepG2 cells. J Biol Chem 1993; 268: 10739-45.
144 Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci 1995; 92: 1851-5.
145 Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997; 17: 33-7.
146 Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999; 82: 1121-6.
147 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
148 Doggen CJM, Bertina RM, Manger Cats V, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999; 82: 115-20.
149 Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Miletich JP. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997; 95: 59-62.
150 Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchioli R, Donati MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 1998; 80: 1029-30.
151 Moghadasian MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. Clinical evidence and genetic and metabolic background. Arch Intern Med 1997; 157: 2299-308.
152 Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-5.
153 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
154 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
155 Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease. Causal or casual? Arch Intern Med 2000; 160: 422-34.
156 Lindgren A, Brättstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26: 795-800.
157 Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am J Cardiol 1996; 77: 759-61.
158 Brättstrom L, Wilcken DEL, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The results of a meta-analysis. Circulation 98: 2520-6.
159 Hajjar KA, Nachman RL. The role of lipoprotein(a) in atherosclerosis and thrombosis. Annu Rev Med 1996; 47: 423-42.
160 Boerwinkle E, Leffert CC, lin J, Lackner C, Chiesa G, Hobbs H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein concentrations. J Clin Invest 1992; 90: 52-60.
161 Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170-6.
162 Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin-binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-5.
163 Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1: 256-9.
164 Dangas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, Ambrose JA, Fallon JT. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998; 32: 2035-42.
165 Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and stroke. J Clin Pathol 2000; 53: 487-96.
166 Tyrrell J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med 1992; 232: 349-52.
167 Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994; 271: 999-1003.
168 Cremer P, Nagel D, Labrot B, Mann H, Mache R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol, and other risk factors; results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J. Clin Invest 1994; 24: 444-53.
169 Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet 1994; 43: 75-9.
170 Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996; 276: 544-8.
171 Wild SH, Fortmann SP, Marcovina SM. A prospective case control study of elevated lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 1997; 17: 239-45.
172 Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
173 Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
174 Cantin B, Gagnon F, Moorjani S, Després JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-25.
175 Ridker PM. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. Trends Cardiovasc Med 1995; 5: 225-9.
176 Maher VMG, Brown G, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-4.
177 Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study. Circulation 1999; 100: 1154-60.
178 Røsby O, Berg K. LPA gene: interaction between the apolipoprotein(a) size (‘kringle IV’ repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J Intern Med 2000; 247: 139-52.
179 Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-34.
180 Ireland H, Kunz G, Kyrialkoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-8.
181 Doggen CJM, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ, Manger Cats V, Ireland H. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998; 08: 743-8.
182 Kunz G, Ireland HA, Stubbs PJ, Kahan M, Coulton GC, Lane DA. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood 2000; 95: 569-76.
183 Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, Isaaz K, Blanc JJ. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000; 83: 822-5.
184 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on Fibrongen. Thromb Haemost 1995; 73: 151-61.
185 Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptiblity to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330: 1041-6.
186 Spielman RS, Ewens WJ. The TDT, and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 1996; 59: 983-9.